Graziano Seghezzi is a member of the Board of Directors ofTenpoint Therapeutics. He is currently Managing Partner at Sofinnova CapitalFunds and serves as active member of the investment team. Graziano serves onthe Board of Directors of several companies he helped create and finance,including GlycoEra, Enthera, HotSpot Therapeutics, EryDel, Inotrem, MissionTherapeutics and Crescendo Biologics. He is responsible for a number ofsubstantial exits, including Corvidia Therapeutics, which was sold to NovoNordisk for €2.1 billion in 2020; Hookipa Pharma, floated on the Nasdaq in2019; GlycoVaxyn, sold to GlaxoSmithKline in 2015, and Omthera Pharmaceuticals,which went public on the Nasdaq in 2013 and was then sold to AstraZeneca thesame year. He has also been the main driver behind Sofinnova Partners’ growingpresence in his native Italy, establishing the country’s first biotechaccelerator, BiovelocITA, in 2015, and the Sofinnova Telethon Fund in 2018. Hestarted his career in venture capital in 2001 at Sofinnova Partners and was atIndex Ventures from 2003 to 2006, returning to Sofinnova following 2006. Priorto that, Graziano spent five years working in academic research at New YorkUniversity’s School of Medicine, studying oncology and cardiovascular diseases.
Graziano holds a degree in genetics and microbiology fromthe University of Pavia, Italy, and an MBA from RSM-Erasmus University in theNetherlands.
